INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics – NKTR
(NASDAQ:NKTR), NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Nektar and certain of its officers and/or directors have engaged […]